The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

People with scalp psoriasis may experience itchy ... The infection is highly transmissible and common among young children. Although mild impetigo may clear up independently, prompt treatment ...

In addition, scalp psoriasis occurs in more than half of ... cream 0.05% is under review for the treatment of atopic dermatitis in children ages 2 to 5 by the FDA, with a PDUFA target action ...

Arcutis Biotherapeutics Inc (ARQT) reports a remarkable 196% year-over-year revenue increase, driven by strong demand for ZORYVE and strategic advancements in product offerings.

Plaques are the dry, raised, scaly skin patches (lesions) caused by psoriasis. They’re often itchy and tender. Plaques usually appear on your elbows, knees, lower back, and scalp. If you notice ...

Here are seven businesses that have opened or are coming soon to Prosper. Now open 1. Alders Prosper The new facility is ...

Some health conditions, like psoriasis, eczema, and dandruff, affect the scalp, so you may have extra ... and her active brood of five children. Lydia Johnson, MD, is a board-certified dermatologist.

After speaking to a dermatologist, it became clear that the guilty party may not be the lotions, potions or powders, but London’s infamous hard water.While it’s easy to change the shower line-up, ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...